<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-707" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Losartan</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mulla</surname>
            <given-names>Sana</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Siddiqui</surname>
            <given-names>Waqas J.</given-names>
          </name>
          <aff>Drexel University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sana Mulla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Waqas Siddiqui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-707.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Losartan is an angiotensin receptor blocker (ARB)&#x000a0;approved by the US Food and Drug Administration (FDA) for the treatment of several medical conditions, including hypertension and diabetic nephropathy. Losartan&#x000a0;inhibits angiotensin II&#x02013;induced vasopressin release, adrenal catecholamine release, rapid and slow pressor responses, thirst, cellular hypertrophy and hyperplasia, noradrenergic neurotransmission, and sympathetic tone increase.&#x000a0;</p>
        <p>In addition, losartan inhibits angiotensin II&#x02013;induced vasoconstriction and the effects of aldosterone, thereby lowering blood pressure. ARBs exhibit renoprotective effects in type 2 diabetes. In hypertension&#x000a0;with left ventricular hypertrophy, losartan inhibits angiotensin II-induced cardiac remodeling, consequently reducing the risk of stroke in these patients.&#x000a0;This activity reviews the use of&#x000a0;losartan, including indications, mechanism of action, contraindications, pharmacokinetics, adverse event profiles, eligible patient populations, and monitoring. This activity also highlights the critical role of the interprofessional healthcare team in managing hypertension and diabetic nephropathy with losartan.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for losartan therapy, including hypertension and diabetic nephropathy, based on patient-specific clinical presentations and guidelines.</p></list-item><list-item><p>Implement appropriate dosing strategies for losartan based on patient-specific factors, such as renal function and comorbidities.</p></list-item><list-item><p>Apply knowledge of potential adverse effects of losartan, including hyperkalemia and angioedema, to promptly recognize and manage adverse reactions.</p></list-item><list-item><p>Collaborate with other healthcare team members to ensure comprehensive care for patients prescribed losartan when managing complex cases involving losartan therapy to optimize patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=707&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=707">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-707.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Losartan is an angiotensin receptor blocker (ARB)&#x000a0;approved by the US Food and Drug Administration (FDA) for the treatment of several medical conditions, including hypertension and diabetic nephropathy.</p>
        <p><bold>Hypertension:</bold> ARBs such as losartan are first-line therapy for stage 1 hypertension, as are thiazide diuretics, calcium channel blockers, and angiotensin-converting enzyme inhibitors (ACEis). In patients with&#x000a0;atherosclerotic cardiovascular disease (ASCVD) risk greater than or equal to 10%, combination therapy is used to&#x000a0;maintain blood pressure. ARB II is useful as monotherapy in the absence of comorbidities such as diabetes,&#x000a0;cerebrovascular disease, ischemic heart disease, heart failure, and chronic kidney disease.<xref ref-type="bibr" rid="article-707.r1">[1]</xref></p>
        <p><bold>Diabetic nephropathy:</bold> In patients with type 2 diabetes and hypertension, losartan treats diabetic nephropathy with&#x000a0;increased serum creatinine (SCr) and&#x000a0;proteinuria. ARBs are renoprotective in type 2 diabetes.<xref ref-type="bibr" rid="article-707.r2">[2]</xref></p>
        <p><bold>Hypertension with left ventricular hypertrophy:</bold> In hypertension&#x000a0;with left ventricular hypertrophy, losartan inhibits angiotensin II-induced cardiac remodeling, consequently reducing the risk of stroke in these patients.</p>
        <p>
<bold>Off-Label&#x000a0;Uses</bold>
</p>
        <p>Losartan is used for Marfan syndrome, acute coronary syndrome, stable coronary artery disease, and intolerance&#x000a0;to ACEis.<xref ref-type="bibr" rid="article-707.r3">[3]</xref>&#x000a0;A study involving older patients with heart failure, the Evaluation of Losartan in the Elderly Study (ELITE), concluded that compared to captopril, losartan correlated with lower mortality and was tolerated better than captopril.<xref ref-type="bibr" rid="article-707.r4">[4]</xref>&#x000a0;The ELITE II study concluded that losartan was as competent as captopril in improving heart failure-related outcomes, the New York Heart Association (NYHA) functional class, and quality of life.<xref ref-type="bibr" rid="article-707.r5">[5]</xref><bold>&#x000a0;</bold></p>
        <p>According to the joint American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA) guidelines published in 2022, ARBs, such as losartan, are acknowledged as essential components of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF)&#x000a0;left ventricular ejection fraction (LVEF &#x02264;40%).<xref ref-type="bibr" rid="article-707.r6">[6]</xref>&#x000a0;As per 2023 guidelines by ACC/AHA, ARBs are also considered for managing heart failure with preserved ejection fraction (HFpEF - LVEF &#x0003e;50%).<xref ref-type="bibr" rid="article-707.r7">[7]</xref></p>
      </sec>
      <sec id="article-707.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Angiotensinogen is converted to angiotensin I by an enzyme, renin, released from the kidney's juxtaglomerular apparatus. ACE converts angiotensin I, an inactive decapeptide, to angiotensin II, an active octapeptide. Losartan is a selective and competitive ARB II at the AT1 receptor site, resulting in a compensatory elevation of renin and angiotensin I levels.&#x000a0;The drug binds with high affinity to the AT1 receptor and is more than 10000 fold more selective for the AT1 receptor than the AT2 receptor.</p>
        <p>Losartan&#x000a0;inhibits angiotensin II&#x02013;induced vasopressin release, adrenal catecholamine release, rapid and slow pressor responses, thirst, cellular hypertrophy and hyperplasia, noradrenergic neurotransmission, and sympathetic tone increase. In addition, losartan inhibits angiotensin II&#x02013;induced vasoconstriction and the effects of aldosterone, thereby lowering blood pressure. Losartan increases the urinary flow and excretion of sodium, potassium, chloride, magnesium, uric acid, calcium, and phosphate. Compared to ACEi, ARB II effectively inhibits the renin-angiotensin system, not affecting the response to bradykinin.<xref ref-type="bibr" rid="article-707.r8">[8]</xref>&#x000a0;For this reason, the&#x000a0;non-renin-angiotensin effects, for example, cough and angioedema, are not commonly seen with ARBs.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Losartan is well absorbed orally but undergoes extensive first-pass metabolism.&#x000a0;The systemic bioavailability is approximately 33%.&#x000a0;The onset of action of losartan is 6 hours and lasts approximately 24 hours.</p>
        <p><bold>Distribution: </bold>Losartan's plasma protein binding (PPB) is high, with approximately 98.7% of losartan bound to plasma proteins; the active metabolite E-3174 has a PPB of approximately 99.8%. The volume of distribution is around 34 L for losartan and 12 L for the metabolite.<xref ref-type="bibr" rid="article-707.r9">[9]</xref></p>
        <p><bold>Metabolism: </bold>Hepatic P450 enzymes CYP2C9 and CYP3A4 metabolize losartan to a more potent 5-carboxylic acid metabolite, EXP 3174.<xref ref-type="bibr" rid="article-707.r10">[10]</xref></p>
        <p><bold>Elimination: </bold>The half-lives of losartan and active metabolite (EXP 3174) are 1.5 to 2 hours and 6 to 9 hours, respectively. The plasma clearance of losartan and EXP 3174 are through the kidney and liver, respectively. Neither losartan&#x000a0;nor&#x000a0;the metabolite accumulates in the body at therapeutic doses.</p>
      </sec>
      <sec id="article-707.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Losartan&#x000a0;does not interact with the intake of food.&#x000a0;The drug is well absorbed but slower with food. However, the administration is best when given at about the same time daily.<xref ref-type="bibr" rid="article-707.r11">[11]</xref>&#x000a0;The FDA has approved the fixed drug combination of losartan/hydrochlorothiazide.<xref ref-type="bibr" rid="article-707.r12">[12]</xref><xref ref-type="bibr" rid="article-707.r13">[13]</xref>&#x000a0;Losartan/hydrochlorothiazide combination medication has&#x000a0;3 strengths&#x02014;50/12.5 mg, 100/12.5 mg, and 100/25 mg.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Hypertension:</bold> The typical initial dosage for losartan potassium tablets in adults is 50 mg daily. The losartan dosage can be increased to a maximum of 100 mg daily. However, for patients who may have low intravascular volume and are already on diuretic therapy, a lower starting dose of 25 mg is recommended. The American College of Rheumatology suggests losartan as the preferred anti-hypertensive drug for patients with gout and hypertension.<xref ref-type="bibr" rid="article-707.r14">[14]</xref><bold/></p>
        <p><bold>Heart failure: </bold>According to ACC/AHA 2022 guidelines, the recommended starting dosage of losartan is&#x000a0;25 to 50 mg daily. The target dosage is 50&#x000a0;to 150 mg daily.<xref ref-type="bibr" rid="article-707.r6">[6]</xref>&#x000a0;<bold/></p>
        <p><bold>Diabetic nephropathy:</bold> The starting dosage of losartan in diabetic nephropathy is 50 mg daily. Based on the patient's response, the losartan dosage may be titrated to 100 mg daily.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>The recommended initial dosage of losartan is 25 mg for patients with mild-to-moderate hepatic impairment. Losartan and its active metabolite concentrations may be higher in these patients than in healthy volunteers. Losartan has not been investigated in patients with severe hepatic impairment.</p>
        <p><bold>Renal impairment:</bold> Patients with renal insufficiency may have higher concentrations of losartan and its active metabolite than normal renal function. Dosage adjustment is generally only necessary if the patient is also volume-depleted.</p>
        <p><bold>Pregnancy considerations:</bold> Neonates with a history of in-utero exposure to losartan should be observed for hypotension, oliguria, and hyperkalemia. If these complications occur, clinicians should provide supportive measures to support blood pressure and renal function, including the consideration of exchange transfusions or dialysis.&#x000a0;As per the guidelines provided by the American College of Obstetricians and Gynecologists (ACOG), avoiding exposure to ARBs during the first trimester of pregnancy is advised. ARBs are fetopathic and increase the risk of congenital malformations, including renal dysgenesis, calvarial hypoplasia, and fetal growth restriction. For additional information, refer to the Box Warning section.<xref ref-type="bibr" rid="article-707.r15">[15]</xref></p>
        <p><bold>Breastfeeding considerations: </bold>Due to the lack of available information regarding the use of losartan during breastfeeding, it is advisable to consider alternative medications, particularly when nursing a newborn or preterm infant.<xref ref-type="bibr" rid="article-707.r16">[16]</xref></p>
        <p><bold>Pediatric patients: </bold>The effectiveness and safety of losartan have been established in pediatric patients with hypertension aged 6 to 16. However, losartan's use is unproven&#x000a0;in patients under&#x000a0;6 or with glomerular filtration (GFR) less than 30 mL/min/1.73 m&#x000b2;. For children with hypertension, the recommended starting dosage is 0.7 mg/kg (up to a maximum of 50 mg) daily, administered either as a tablet or suspension. The dosage should be adjusted based on the response to blood pressure. Higher doses exceeding 1.4 mg/kg (or above 100 mg) per day have not been studied in pediatric patients.</p>
        <p><bold>Older patients:</bold> No significant differences in effectiveness or safety have been observed between older patients (65 and older) and younger patients in controlled clinical studies. However, older individuals may display greater sensitivity to the medication. The healthcare provider should consider initiating losartan at a low dose and assessing for comorbidities and polypharmacy in the patient.</p>
      </sec>
      <sec id="article-707.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The primary adverse effects of losartan, including hyperkalemia, renal insufficiency, and angioedema, are reported.<xref ref-type="bibr" rid="article-707.r17">[17]</xref></p>
        <p><bold>Greater than 10%:&#x000a0;</bold>Adverse effects greater than 10% include fatigue, hypoglycemia, anemia, urinary tract infection, chest pain, weakness, diarrhea, and cough (although the incidence of a&#x000a0;cough is&#x000a0;lower compared to&#x000a0;ACEi therapy).</p>
        <p><bold>Between 1%&#x000a0;and&#x000a0;10%:&#x000a0;</bold>Adverse effects occurring between 1% and 10% include upper respiratory tract infection, hypotension, dizziness, cellulitis, gastritis, and nausea.</p>
        <p><bold>Frequently not defined/post-marketing surveillance:&#x000a0;</bold>The potential adverse effects frequently not defined during post-marketing surveillance include angioedema,<xref ref-type="bibr" rid="article-707.r18">[18]</xref>&#x000a0;edema/swelling, hypotension in hypovolemic patients, asthenia, headache, malaise, nausea, abdominal pain, hyperkalemia, back pain, worsening renal failure, tremors, and dysarthria.<xref ref-type="bibr" rid="article-707.r19">[19]</xref></p>
      </sec>
      <sec id="article-707.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Losartan is contraindicated in hypersensitivity to losartan or any of its components.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>Drugs causing hyperkalemia:</bold>&#x000a0;When losartan is coadministered with other drugs that can increase serum potassium levels, it may lead to hyperkalemia.&#x000a0;Clinicians should monitor serum potassium levels.</p>
        <p><bold>Lithium:</bold>&#x000a0;Simultaneous use of lithium and ARBs, including losartan,&#x000a0;is associated with elevated serum lithium concentrations and toxicity. Regular monitoring of serum lithium levels is recommended.</p>
        <p><bold>Nonsteroidal anti-inflammatory drugs (NSAIDs)</bold>: In older patients with volume depletion, those on diuretic therapy, or individuals with impaired renal function, the coadministration of NSAIDs, including selective COX-2 inhibitors, with ARBs such as losartan, may result in a decline in renal function, including potential acute kidney injury. These effects are typically reversible. Periodic monitoring of renal function is advised for patients receiving losartan in combination with NSAIDs. NSAIDs can decrease the antihypertensive effects of ARB II, including losartan.</p>
        <p><bold>Dual blockade of the renin-angiotensin system:</bold>&#x000a0;Concurrent use of ARBs, ACEi, or aliskiren (renin inhibitor) in combination is associated with increased risks of hypotension, syncope, hyperkalemia, and acute kidney injury compared to monotherapy.<xref ref-type="bibr" rid="article-707.r20">[20]</xref></p>
        <p><bold>Aliskiren:</bold>&#x000a0;In patients with diabetes, the coadministration of aliskiren with losartan is not recommended.<xref ref-type="bibr" rid="article-707.r21">[21]</xref> Additionally, aliskiren with losartan should be avoided in patients with renal impairment (GFR &#x0003c;60 mL/min).</p>
        <p>
<bold>Box Warning</bold>
</p>
        <p><bold>Pregnancy:&#x000a0;</bold>Losartan is contraindicated in pregnancy. As losartan acts on the renin-angiotensin system, it causes oligohydramnios, resulting in fetal lung hypoplasia and skeletal deformities. Potential neonatal adverse effects are skull hypoplasia, hypotension, anuria, renal failure, and death. Therefore, therapy with the drug should be discontinued&#x000a0;when pregnancy is detected.<xref ref-type="bibr" rid="article-707.r22">[22]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p><bold>Angioedema:</bold> The incidence of angioedema and cough with ARBs is less than ACEi. However,&#x000a0;this may involve the airway and intestine, causing abdominal pain. Patients with previous episodes of angioedema associated with ACEi, hereditary angioedema, or idiopathic angioedema may&#x000a0;have augmented risk. Frequent monitoring is necessary for such patients. Losartan should be discontinued if any episode of angioedema occurs, and the patient should be treated aggressively with intramuscular epinephrine. Patients should not be restarted on losartan after experiencing angioedema.<xref ref-type="bibr" rid="article-707.r23">[23]</xref></p>
        <p><bold>Hyperkalemia:</bold> Risk factors include using potassium-sparing diuretics, potassium supplements, and potassium salts. In such cases, potassium levels should be monitored closely.</p>
        <p><bold>Hypotension:</bold>&#x000a0;Healthcare providers should consider initiating losartan at a low dose and assessing for comorbidities and polypharmacy in the patient.</p>
        <p><bold>Renal function:</bold> Losartan may&#x000a0;diminish renal function, resulting in elevated&#x000a0;SCr levels, oliguria, azotemia, and acute renal failure. Losartan should be discontinued if a critical decrease in renal function is observed. It should be used cautiously in cases of renal artery stenosis and avoided altogether in bilateral renal artery stenosis.</p>
        <p><bold>Hepatic and renal impairment:</bold>&#x000a0;Losartan should be cautiously used in patients with previous or current hepatic and renal impairment.</p>
      </sec>
      <sec id="article-707.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Healthcare providers should monitor blood pressure, renal function (blood urea nitrogen and SCr levels), and potassium levels in patients prescribed losartan.<xref ref-type="bibr" rid="article-707.r24">[24]</xref></p>
        <p><bold>Heart failure:</bold> In&#x000a0;cases of heart failure, healthcare providers should reevaluate the patient's blood pressure, including orthostatic measurements, renal function, and serum potassium levels. Patients with hyponatremia, systolic blood pressure (SBP) below 80 mm Hg, diabetes, and impaired renal function require close monitoring. According to the ACC/AHA/HFSA 2022 guidelines, healthcare providers should monitor BNP/NT-ProBNP levels for risk stratification.<xref ref-type="bibr" rid="article-707.r6">[6]</xref></p>
        <p><bold>Hypertension:&#x000a0;</bold>For confirmed hypertension with known cardiovascular disease (CVD) or patients with a 10-year ASCVD risk &#x02265;10%, the recommended blood pressure target is less than 130/80 mm Hg. The ACC and AHA recommend a thorough follow-up evaluation for cardiovascular patients, which includes assessing blood pressure control, orthostatic hypotension, medication adverse effects, medication and lifestyle modification, dosage adjustments, laboratory testing, and target organ damage assessments. These evaluations are essential for the effective management of hypertension.<xref ref-type="bibr" rid="article-707.r25">[25]</xref></p>
        <p><bold>Diabetes and hypertension:&#x000a0;</bold>Per the guidelines of the American Diabetes Association, it is not recommended to discontinue ARBs in cases of minor increases in&#x000a0;SCr levels (&#x0003c;30%) unless concurrent volume depletion exists.<xref ref-type="bibr" rid="article-707.r26">[26]</xref>&#x000a0;The treatment goal for&#x000a0;individuals aged 18 to 65 is to achieve a SBP below 140 mm Hg and a diastolic blood pressure (DBP) below 90 mm Hg. The goal for patients aged 18 to 65 at high risk of CVD is SBP less than 130 mm Hg and DBP less than 80 mm Hg if this is achievable without undue treatment burden. For patients aged 65 and older who are healthy or of complex/intermediate health, the goal of therapy is SBP less than 140 mm Hg and DBP greater than 90 mm Hg. The goal of treatment for patients aged 65 and older and of very complex or poor health is SBP less than 150 mm Hg and DBP less than 90 mm Hg.</p>
      </sec>
      <sec id="article-707.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In a recent case report, a female patient aged 34 with a medical history of asthma, hypertension, and chronic respiratory failure had an overdose of losartan. She intentionally ingested 30 tablets of 25 mg of losartan in a suicide attempt. Illicit substance use was ruled out through a negative urine drug screen. During her hospitalization, the patient developed acute kidney injury and hyperkalemia. Based on the patient's complaint of diffuse abdominal pain, elevated lipase levels (161 U/L), and computed tomography (CT) imaging findings, acute pancreatitis was diagnosed. Supportive care, including fluid resuscitation, pain management, and continuous monitoring of laboratory parameters, was provided, gradually improving her condition. The healthcare team should be mindful of the possibility of drug-induced acute pancreatitis following an overdose of losartan from acute kidney injury and hyperkalemia.<xref ref-type="bibr" rid="article-707.r27">[27]</xref></p>
        <p>No&#x000a0;consensus recommendation for overdosing on ARBs exists. The chronic use of ARBs at standard doses can block the renin-angiotensin and sympathetic nervous systems, leading to shock that may not respond to catecholamines. In cases of refractory shock, vasopressin can be considered.<xref ref-type="bibr" rid="article-707.r28">[28]</xref>&#x000a0;No antidote for losartan is available, and hemodialysis is ineffective in removing losartan from circulation due to the high PPB, as mentioned in pharmacokinetics. Supportive care should be instituted&#x000a0;for overdose cases.</p>
      </sec>
      <sec id="article-707.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Although any clinician can prescribe losartan for hypertension and diabetic nephropathy, regular monitoring of renal function and blood pressure by the interprofessional healthcare team is essential. Input from heart failure specialists or cardiologists regarding GDMT is recommended for evidence-based treatment. Losartan is effective for hypertension and can be incorporated into long-term therapy plans, but its optimal use still necessitates the participation of an interprofessional team to optimize treatment outcomes.</p>
        <p>When initially prescribed, a pharmacist must verify&#x000a0;appropriate dosing, conduct medication reconciliation, and counsel the patient regarding losartan. Nursing staff also play a crucial role in offering valuable patient counseling, addressing inquiries, and evaluating therapeutic effectiveness during subsequent visits. The pharmacist or nursing staff should promptly communicate any concerns to the prescriber to facilitate timely therapeutic adjustments through shared decision-making. In cases of overdose, consultation with a medical toxicologist is recommended. An interprofessional team approach, fostering open communication among physicians, advanced practice practitioners, specialists, nurses, pharmacists, and toxicologists, is pivotal in optimizing patient outcomes while mitigating potential adverse effects associated with losartan therapy.</p>
      </sec>
      <sec id="article-707.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=707&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=707">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/707/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=707">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-707.s11">
        <title>References</title>
        <ref id="article-707.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Majed</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Assiri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Khalil</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Abdel-Aziz</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Losartan: Comprehensive Profile.</article-title>
            <source>Profiles Drug Subst Excip Relat Methodol</source>
            <year>2015</year>
            <volume>40</volume>
            <fpage>159</fpage>
            <page-range>159-94</page-range>
            <pub-id pub-id-type="pmid">26051686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruggenenti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Dual renin-angiotensin system blockade for nephroprotection.</article-title>
            <source>Nephrol Ther</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>13 Suppl 1</volume>
            <fpage>S43</fpage>
            <page-range>S43-S45</page-range>
            <pub-id pub-id-type="pmid">28577742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>den Hartog</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Franken</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Zwinderman</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Timmermans</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Scholte</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>de Waard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Spijkerboer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pals</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Groenink</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutations.</article-title>
            <source>Neth Heart J</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>11</issue>
            <fpage>675</fpage>
            <page-range>675-681</page-range>
            <pub-id pub-id-type="pmid">27704402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Meurers</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cowley</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Deedwania</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Ney</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Snavely</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>PI</given-names>
              </name>
            </person-group>
            <article-title>Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).</article-title>
            <source>Lancet</source>
            <year>1997</year>
            <month>Mar</month>
            <day>15</day>
            <volume>349</volume>
            <issue>9054</issue>
            <fpage>747</fpage>
            <page-range>747-52</page-range>
            <pub-id pub-id-type="pmid">9074572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Konstam</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Neaton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Poole-Wilson</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dasbach</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Carides</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Dickstein</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Riegger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Camm</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Bradstreet</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>EP</given-names>
              </name>
              <collab>ELITE II Investigators</collab>
            </person-group>
            <article-title>Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).</article-title>
            <source>Am Heart J</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>150</volume>
            <issue>1</issue>
            <fpage>123</fpage>
            <page-range>123-31</page-range>
            <pub-id pub-id-type="pmid">16084158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>145</volume>
            <issue>18</issue>
            <fpage>e895</fpage>
            <page-range>e895-e1032</page-range>
            <pub-id pub-id-type="pmid">35363499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Panjrath</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Amancherla</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2023</year>
            <month>May</month>
            <day>09</day>
            <volume>81</volume>
            <issue>18</issue>
            <fpage>1835</fpage>
            <page-range>1835-1878</page-range>
            <pub-id pub-id-type="pmid">37137593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huo</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>YH</given-names>
              </name>
            </person-group>
            <article-title>Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis.</article-title>
            <source>Nephrology (Carlton)</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>9</issue>
            <fpage>605</fpage>
            <page-range>605-14</page-range>
            <pub-id pub-id-type="pmid">23869492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ripley</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?</article-title>
            <source>Int J Nephrol Renovasc Dis</source>
            <year>2010</year>
            <volume>3</volume>
            <fpage>93</fpage>
            <page-range>93-8</page-range>
            <pub-id pub-id-type="pmid">21694934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <chapter-title>Losartan</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">31643181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dickstein</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Timmermans</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>7</volume>
            <issue>11</issue>
            <fpage>1897</fpage>
            <page-range>1897-914</page-range>
            <pub-id pub-id-type="pmid">15991937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Lyle</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Kizer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>H&#x000f8;ieggen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Os</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2007</year>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299-305</page-range>
            <pub-id pub-id-type="pmid">17703637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ueda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Imaizumi</surname>
                <given-names>T</given-names>
              </name>
              <collab>MAPPY Study Investigators</collab>
            </person-group>
            <article-title>Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension--a prospective, randomized, open-labeled, parallel-group, multicenter trial.</article-title>
            <source>Hypertens Res</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>7</issue>
            <fpage>708</fpage>
            <page-range>708-14</page-range>
            <pub-id pub-id-type="pmid">22399096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brignardello-Petersen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abeles</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gelber</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Harrold</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Libbey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mount</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sims</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Danve</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Lenert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qasim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sehra</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>TSK</given-names>
              </name>
              <name>
                <surname>Toprover</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>2020 American College of Rheumatology Guideline for the Management of Gout.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>879</fpage>
            <page-range>879-895</page-range>
            <pub-id pub-id-type="pmid">32390306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>e26</fpage>
            <page-range>e26-e50</page-range>
            <pub-id pub-id-type="pmid">30575676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Losartan</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>1</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30000685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bolotova</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chaudhri</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Marcos</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Sahib</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Koraishy</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Skopicki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mallipattu</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Safety, tolerability, and outcomes of losartan use in patients hospitalized with SARS-CoV-2 infection: A feasibility study.</article-title>
            <source>PLoS One</source>
            <year>2020</year>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>e0244708</fpage>
            <pub-id pub-id-type="pmid">33378401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vedantam</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Magacha</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Vedantam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dahya</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Abu-Heija</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>A Case Report of Losartan Induced Angioedema.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>e36525</fpage>
            <pub-id pub-id-type="pmid">37090415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fishman</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Degu</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salabei</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Possible Association of Tremors and Dysarthria with Losartan Use: A Case Report.</article-title>
            <source>Cureus</source>
            <year>2019</year>
            <month>Dec</month>
            <day>13</day>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>e6374</fpage>
            <pub-id pub-id-type="pmid">31938654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esteras</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Perez-Gomez</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Rodriguez-Osorio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fernandez-Fernandez</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function.</article-title>
            <source>Ther Adv Drug Saf</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>166</fpage>
            <page-range>166-76</page-range>
            <pub-id pub-id-type="pmid">26301070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woo</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Choong</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Foo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fook-Chong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Anantharaman</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Aliskiren and losartan trial in non-diabetic chronic kidney disease.</article-title>
            <source>J Renin Angiotensin Aldosterone Syst</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>515</fpage>
            <page-range>515-22</page-range>
            <pub-id pub-id-type="pmid">24742970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Da&#x000ef;kha-Dahmane</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Levy-Beff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jugie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lenclen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2006</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>729</fpage>
            <page-range>729-32</page-range>
            <pub-id pub-id-type="pmid">16565869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathey</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Maj</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Scheer</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Fazaal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wedi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wieczorek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amann</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>L&#x000f6;ffler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;ffl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dickel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ganjuur</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hornung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Forkel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greve</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wurpts</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hallberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bygum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Von Buchwald</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Karawajczyk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steffens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stingl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heilmann-Heimbach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mangold</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Wadelius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sachs</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>N&#x000f6;then</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Forstner</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Molecular Genetic Screening in Patients With ACE Inhibitor/Angiotensin Receptor Blocker-Induced Angioedema to Explore the Role of Hereditary Angioedema Genes.</article-title>
            <source>Front Genet</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>914376</fpage>
            <pub-id pub-id-type="pmid">35923707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <article-title>Comparison chart: Some drugs for HFrEF.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2021</year>
            <month>Jun</month>
            <day>14</day>
            <volume>63</volume>
            <issue>1626</issue>
            <fpage>e1</fpage>
            <page-range>e1-e14</page-range>
            <pub-id pub-id-type="pmid">34181629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>71</volume>
            <issue>19</issue>
            <fpage>e127</fpage>
            <page-range>e127-e248</page-range>
            <pub-id pub-id-type="pmid">29146535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association Professional Practice Committee</collab>
            <article-title>11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022.</article-title>
            <source>Diabetes Care</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>45</volume>
            <issue>Suppl 1</issue>
            <fpage>S175</fpage>
            <page-range>S175-S184</page-range>
            <pub-id pub-id-type="pmid">34964873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khatri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chacko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chamay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kashfi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Delayed-Onset Losartan-Induced Pancreatitis Secondary to an Overdose: A Case Report.</article-title>
            <source>J Investig Med High Impact Case Rep</source>
            <year>2023</year>
            <season>Jan-Dec</season>
            <volume>11</volume>
            <fpage>23247096231165737</fpage>
            <pub-id pub-id-type="pmid">37052072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-707.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsushime</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kuriyama</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Vasopressin for persistent hypotension due to amlodipine and olmesartan overdose: A case report.</article-title>
            <source>Ann Med Surg (Lond)</source>
            <year>2021</year>
            <month>May</month>
            <volume>65</volume>
            <fpage>102292</fpage>
            <pub-id pub-id-type="pmid">33981424</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
